Compare WIW & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WIW | DNA |
|---|---|---|
| Founded | 2004 | 2008 |
| Country | United States | United States |
| Employees | N/A | 485 |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 518.8M | 455.8M |
| IPO Year | N/A | N/A |
| Metric | WIW | DNA |
|---|---|---|
| Price | $8.35 | $5.95 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 212.9K | ★ 1.1M |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | ★ 11.14% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.33 | $5.00 |
| 52 Week High | $9.03 | $17.58 |
| Indicator | WIW | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 28.24 | 36.90 |
| Support Level | N/A | N/A |
| Resistance Level | $8.84 | $10.05 |
| Average True Range (ATR) | 0.05 | 0.47 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 2.79 | 5.07 |
Western Asset Inflation-Linked Opportunities and Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to provide current income. Capital appreciation, when consistent with current income, is a secondary investment objective. The fund operates as a single operating segment, which is an investment portfolio.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.